Search Results 2721-2730 of 17675 for rheumatoid arthritis

  1. Jason Howland | Mayo Clinic News Network - Page 27 of 38

    Exercise is an important factor when living a healthy life. But if you only have time to be physically active occasionally, there are some helpful[...] By ...

  2. Publications - Anjali Bhagra, M.D., M.B.A. - Mayo Clinic

    A rare cause of oligoarthritis with septic presentation. BMJ Case Rep. 2018 Apr 17; 2018. View PubMed; Mahapatra S, Bhagra A, Fekadu B, Li Z, Bauer BA, Wahner ...

  3. A Study to Evaluate AMG 701 in Subjects with Multiple Myeloma - Mayo Clinic

    absolute neutrophil count (ANC) x 1.0 x 10^9 /L (without growth factor support);; platelet count ≥ 50 x 10^9 /L (without transfusions within 7 days from ...

  4. Novel stem cell therapy for perianal fistula in pediatric patients with Crohn's disease - Mayo Clinic

    Pediatric onset of Crohn's disease is associated with more-aggressive perianal fistula development. New therapy derives stem cells from patients' fat cells ...

  5. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis - Mayo Clinic

    TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor ...

  6. A comprehensive, expedited approach for nonunions - Mayo Clinic

    Tobacco is one such modifiable risk factor. She recognizes smoking cessation is a challenge. Ultimately, however, she collaborates with the patients needing ...

  7. Clinical trials - Oncology (Medical)

    ... factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation. Assessing Breast Cancer Risk Perception in Hispanic ...

  8. Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis - Mayo Clinic

    Patients must have adequate bone marrow function as defined by the following within 28 days prior to registration: ANC ≥ 1,000 cells/mcl without growth factor ...

  9. Immunotherapy Clinical Trials - Mayo Clinic Research

    Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces ...

  10. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

    ... Factor Xa inhibitors). Pregnant or nursing (lactating) women. Treatment with the following therapies within the specified time period: Monoclonal antibodies ...